Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

For instance, POU was associated with metabolic biomarkers, including increased triglyceride in serum or plasma (beta = 0.04, p = 1.41E−12) and blood glucose (beta = 0.02, p = 4.02E−5), and lower HDL cholesterol (beta = −0.03, p = 7.21E−07), calcium (beta = −0.01, p = 8.00E-04), folate (beta = −0.04, p = 8.70E-04), and calcitriol (beta = −0.02, p = 1.97E−03).

Source: Lab-wide association analyses (LabWAS). View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All participants were drawn from the customer base of 23andMe, Inc., a direct-to-consumer genetics company.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry

Study design awaiting verification · Molecular Psychiatry · 2021

Original publication title

Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry

Sandra Sanchez-Roige; Pierre Fontanillas; Mariela V. Jennings; Sevim B. Bianchi; Yuye Huang; Alexander S. Hatoum; Julia Sealock; Lea K. Davis; Sarah L. Elson; 23andMe Research TeamAgeeMichelle3AlipanahiBabak3AutonAdam3BellRobert K.3BrycKatarzyna3FurlotteNicholas A.3HindsDavid A.3HuberKaren E.3KleinmanAaron3LittermanNadia K.3McCreightJennifer C.3McIntyreMatthew H.3MountainJoanna L.3NoblinElizabeth S.3NorthoverCarrie A. M.3PittsSteven J.3SathirapongsasutiJ. Fah3SazonovaOlga V.3SheltonJanie F.3ShringarpureSuyash3TianChao3TungJoyce Y.3VacicVladimir3WilsonCatherine H.3; Abraham A. Palmer

© The Author(s) 2021, corrected publication 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The growing prevalence of opioid use disorder (OUD) constitutes an urgent health crisis. Ample evidence indicates that risk for OUD is heritable. As a surrogate (or proxy) for OUD, we explored the genetic basis of using prescription opioids ‘not as prescribed’. We hypothesized that misuse of opiates might be a heritable risk factor for OUD. To test this hypothesis, we performed a genome-wide association study (GWAS) of problematic opioid use (POU) in 23andMe research participants of European ancestry (N = 132,113; 21% cases).

We identified two genome-wide significant loci (rs3791033, an intronic variant of KDM4A; rs640561, an intergenic variant near LRRIQ3). POU showed positive genetic correlations with the two largest available GWAS of OUD and opioid dependence (rg = 0.64, 0.80, respectively). We also identified numerous additional genetic correlations with POU, including alcohol dependence (rg = 0.74), smoking initiation (rg = 0.63), pain relief medication intake (rg = 0.49), major depressive disorder (rg = 0.44), chronic pain (rg = 0.42), insomnia (rg = 0.39), and loneliness (rg = 0.28).

Although POU was positively genetically correlated with risk-taking (rg = 0.38), conditioning POU on risk-taking did not substantially alter the magnitude or direction of these genetic correlations, suggesting that POU does not simply reflect a genetic tendency towards risky behavior. Lastly, we performed phenome: and lab-wide association analyses, which uncovered additional phenotypes that were associated with POU, including respiratory failure, insomnia, ischemic heart disease, and metabolic and blood-related biomarkers. We conclude that opioid misuse can be measured in population-based cohorts and provides a cost-effective complementary strategy for understanding the genetic basis of OUD.

Authors’ abstract

The growing prevalence of opioid use disorder (OUD) constitutes an urgent health crisis. Ample evidence indicates that risk for OUD is heritable. As a surrogate (or proxy) for OUD, we explored the genetic basis of using prescription opioids ‘not as prescribed’. We hypothesized that misuse of opiates might be a heritable risk factor for OUD. To test this hypothesis, we performed a genome-wide association study (GWAS) of problematic opioid use (POU) in 23andMe research participants of European ancestry (N = 132,113; 21% cases).

We identified two genome-wide significant loci (rs3791033, an intronic variant of KDM4A; rs640561, an intergenic variant near LRRIQ3). POU showed positive genetic correlations with the two largest available GWAS of OUD and opioid dependence (rg = 0.64, 0.80, respectively). We also identified numerous additional genetic correlations with POU, including alcohol dependence (rg = 0.74), smoking initiation (rg = 0.63), pain relief medication intake (rg = 0.49), major depressive disorder (rg = 0.44), chronic pain (rg = 0.42), insomnia (rg = 0.39), and loneliness (rg = 0.28).

Although POU was positively genetically correlated with risk-taking (rg = 0.38), conditioning POU on risk-taking did not substantially alter the magnitude or direction of these genetic correlations, suggesting that POU does not simply reflect a genetic tendency towards risky behavior. Lastly, we performed phenome: and lab-wide association analyses, which uncovered additional phenotypes that were associated with POU, including respiratory failure, insomnia, ischemic heart disease, and metabolic and blood-related biomarkers. We conclude that opioid misuse can be measured in population-based cohorts and provides a cost-effective complementary strategy for understanding the genetic basis of OUD.

Publication and source details

Original title: Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry

Sandra Sanchez-Roige; Pierre Fontanillas; Mariela V. Jennings; Sevim B. Bianchi; Yuye Huang; Alexander S. Hatoum; Julia Sealock; Lea K. Davis; Sarah L. Elson; 23andMe Research TeamAgeeMichelle3AlipanahiBabak3AutonAdam3BellRobert K.3BrycKatarzyna3FurlotteNicholas A.3HindsDavid A.3HuberKaren E.3KleinmanAaron3LittermanNadia K.3McCreightJennifer C.3McIntyreMatthew H.3MountainJoanna L.3NoblinElizabeth S.3NorthoverCarrie A. M.3PittsSteven J.3SathirapongsasutiJ. Fah3SazonovaOlga V.3SheltonJanie F.3ShringarpureSuyash3TianChao3TungJoyce Y.3VacicVladimir3WilsonCatherine H.3; Abraham A. Palmer

Molecular Psychiatry · 2021

© The Author(s) 2021, corrected publication 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/100005188Tobacco-Related Disease Research Program (TRDRP)T29KT0526T29KT0526T29KT052628IR-0070Sanchez-Roige Sandra Jennings Mariela V. Huang Yuye Palmer Abraham A. https://doi.org/10.13039/100000026U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)5T32DA007261Hatoum Alexander S. https://doi.org/10.13039/100000025U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)1R01MH1133621R01MH1182331R56MH120736Davis Lea K. U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T11:11:02.256146+00:00

DOI: 10.1038/s41380-021-01335-3 · PMC8562028